Symptoms from excessive screen time cost the U.S. $73 billion a year, study finds

Symptoms from excessive screen time cost the U.S.  billion a year, study finds


American workers are spending too much time looking at screens.

More than 104 million people in the U.S., including nearly 70% of people working office jobs, spend upwards of seven hours a day looking at screens, according to a Tuesday report from the Deloitte Economics Institute and the American Optometric Association.

As a result, symptoms of “excessive screen time,” or more than seven hours of screen time a day, are costing the U.S. $73 billion per year, the report said. The figure was determined by analyzing the direct financial costs incurred by health systems, the symptoms’ impact on productivity at work, and their perceived impact on an individual’s well-being.

The omnipresence of screens in everyday life puts people at a higher risk of contending with eye problems like digital eye strain, or DES, which can cause symptoms like neck and back pain, blurred vision, headaches and dry eyes.

Just two hours of screen time per day can induce these symptoms, and if left untreated, the study found they can “lead to decreased productivity, exacerbate other undiagnosed eye conditions and may affect an individual’s sleep quality and mental health.”

However, the adverse impact of conditions like DES, as well as direct costs to the individual, can be mitigated through regular visits to an eye doctor, using eye drops and wearing appropriate glasses, according to the report.

The study found that people with excessive screen time exposure could save as much as $1,920 per person by seeing an optometrist and managing their symptoms.

“These findings further underscore the importance of better screen time habits and receiving annual, in-person comprehensive eye exams with an AOA doctor of optometry to maintain your eye and overall health,” Ronald Benner, president of the AOA said in a release.

A sample of 1,000 survey responses of men and women aged 18 through 64 from across 50 states, as well as a review of existing data and literature, were used to conduct this study, the report said.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More